BEIJING, China, January 26, 2026 —— Gan & Lee Pharmaceuticals. (hereinafter referred to as "Gan & Lee", Stock Code: 603087.SH) has recently achieved a major milestone in its global expansion. A launch event for Insulin Glargine Injection (Brand Name: Basalin™), hosted by its local partner GYPTO PHARMA, was successfully held in Cairo, marking the product's official entry into the Egyptian market. Kai Du, Executive Vice President and Chief Commercial Officer (EVP & CCO) of Gan & Lee, attended the event alongside the company's local partners and prominent Egyptian medical experts to witness this landmark moment.

The successful launch of Basalin™ in Egypt marks a strategic breakthrough for Gan & Lee in the Middle East and North Africa (MENA) market. It also stands as a key practice in advancing the company's internationalization strategy and a proactive response to China's Belt and Road Initiative. During the ceremony, Mr. Kai Du stated: "2026 marks the 70th anniversary of the establishment of diplomatic relations between China and Egypt. Over the past seven decades, the friendship between our two countries has grown from strength to strength. The launch of Basalin™ is a testament to the deepening healthcare cooperation under the Belt and Road Initiative. Going forward, we aim to enhance the quality of life for more patients with more inclusive Chinese solutions."

According to the latest data from the International Diabetes Federation (IDF), the number of adults (aged 20-79) living with diabetes in Egypt has reached 13.2 million, with a diabetes prevalence rate of 19.8%¹. This sizeable patient population has created a sustained demand for diabetes treatments and clinical innovation. Gan & Lee's Insulin Glargine is the first biosimilar insulin from a Chinese company to enter the Egyptian market. As a long-acting insulin product already approved by the European Commission (EC), Basalin™ will significantly improve local access to high-quality treatment, bringing Chinese expertise to advance public health and benefit diabetic patients across the region.

Looking ahead, Gan & Lee will continue to uphold its corporate culture of "Science & Excellence". Aligned with the Belt and Road Initiative, the company aims to deepen global production synergy and technological cooperation. By promoting more high-quality biologics worldwide, Gan & Lee is committed to contributing Chinese wisdom and strength to the global biopharmaceutical stage.

Reference:

1、IDF Diabetes Atlas 11th edition 2025. Available at: https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.